sequana_rgb_300.png
Sequana Medical announces results of Annual and Extraordinary General Meetings of Shareholders
May 27, 2022 12:00 ET | Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION27 May 2022, 06:00 pm CEST Ghent, Belgium – 27 May 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), an innovator in the...
sequana_rgb_300.png
Sequana Medical announces Annual and Extraordinary General Meetings of Shareholders on 27 May 2022
April 27, 2022 01:00 ET | Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION27 April 2022, 07:00 am CEST Publication of Annual Report 2021 Ghent, Belgium – 27 April 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or...
sequana_rgb_300.png
Sequana Medical announces 2021 Full Year Results and 2022 Outlook
April 12, 2022 01:00 ET | Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION12 April 2022, 07:00 CET alfapump® in liver disease Positive results from second interim analysis of POSEIDON pivotal study; encouraging survival data at 12 months...
sequana_rgb_300.png
Sequana Medical to present at Needham’s Healthcare Conference and attend Kempen’s Life Sciences Conference in April 2022
April 08, 2022 01:00 ET | Sequana Medical NV
Ghent, Belgium – 8 April 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), an innovator in the treatment of diuretic-resistant fluid overload in liver disease,...
sequana_rgb_300.png
Sequana Medical announces the completion of alfapump implantations in POSEIDON, the North American pivotal alfapump study
April 05, 2022 01:00 ET | Sequana Medical NV
Reporting of primary endpoint on track for Q4 2022FDA regulatory submission on track for mid-202370% survival of POSEIDON Roll-In patients at one year post-implantation1 compares favourably to...
sequana_rgb_300.png
Sequana Medical Notice of 2021 Full Year Results and Business Update
March 31, 2022 01:00 ET | Sequana Medical NV
Ghent, Belgium – 31 March 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), an innovator in the treatment of diuretic-resistant fluid overload in liver...
sequana_rgb_300.png
Transparency Notifications from Shareholders
March 28, 2022 12:00 ET | Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION 28 March 2022, 6 p.m. CET Ghent, Belgium – 28 March 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), an innovator in...
sequana_rgb_300.png
Transparency Notifications from Shareholders
March 18, 2022 13:00 ET | Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION 18 March 2022, 6 p.m. CET Ghent, Belgium – 18 March 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), an innovator in...
sequana_rgb_300.png
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
March 10, 2022 12:00 ET | Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION10 March 2022, 18:00 CET Ghent, Belgium, 10 March 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), an innovator in the...
sequana_rgb_300.png
Sequana Medical to present at BioCapital Europe and Oppenheimer’s Annual Healthcare Conference
March 09, 2022 01:00 ET | Sequana Medical NV
Ghent, Belgium – 09 March 2022 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid overload in liver...